Clinical opinion

Extracorporeal membrane oxygenation in adults

JP Johnston
Specialist Registrar in Anaesthesia, Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK

TITLE  Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial

AUTHORS  Peek GJ, Mugford M, Tiruvoipati R et al.


DECLARATION Of INTERESTS  No conflict of interests declared.

SUMMARY  This paper is the summation of five years’ work studying clinical and economic outcomes comparing the use of extracorporeal membrane oxygenation (ECMO) and conventional medical care to treat severe respiratory failure. Extracorporeal membrane oxygenation is an intervention, which, like cardiac bypass, can support a failing myocardium when used in a veno-arterial mode. This trial, Conventional ventilation or ECMO for Severe Adult Respiratory Failure (CESAR), studied pulmonary support alone, using ECMO in the veno-venous mode.

Peek and colleagues screened 766 patients with respiratory failure between July 2001 and August 2006. A significant number were excluded, the most significant factors being ECMO bed availability, an inappropriate lung injury score (LIS) or difficult ventilation for greater than seven days. A total of 180 subjects were enrolled; 90 were randomised to the treatment limb and 90 to the conventional medical care limb. The primary outcomes studied were death or significant disability at six months post-randomisation. A holistic range of secondary outcome measures were also studied.

In an intention-to-treat analysis the primary outcome of death or severe disability (37% vs 53%) did reach statistical significance, despite some missing data relating to disability status in the conventional treatment limb. On further analysis mortality outcomes alone, without inclusion of disability scoring, at six months in the treatment vs conventional limbs (37% vs 45%, p=0.07), did not reach statistical significance.

Better outcomes were demonstrated in the treatment group despite only 76% of those randomised and transferred to a specialist centre actually receiving ECMO. The other 24%, if they had not died prior to arrival at the treatment centre, received only conservative management strategies that would be available in most intensive care units. The study group therefore recommend the transfer of adult patients with acute severe respiratory failure to a centre with the ability to initiate an ECMO-based management protocol.

OPINION  Extracorporeal membrane oxygenation is not a new technique. Indeed, it has become accepted in neonatal medical practice as a standard of care. In the UK, an ECMO service is provided by six centres registered with the Extracorporeal Life Support Organisation (ELSO). Only one, Glenfield Hospital in Leicester, currently provides a service for adult patients. As such, the CESAR study was in essence a single-centre trial, despite individual control patients receiving care in their referring intensive care unit (ICU). Blinding was impossible as all ECMO-randomised patients were transferred to a single site. An inherent degree of bias cannot therefore be excluded.

Results from the CESAR trial demonstrate a trend towards improved survival using ECMO vs conventional care in adults with severe acute respiratory failure, defined by a Murray Lung Injury Score >3.0. This trend is not statistically significant, which is consistent with two major previous trials published in 1979 and 1994.1,2 In the CESAR trial, however, ECMO was shown to be beneficial when survival without severe disability was substituted as the primary endpoint. This significance could be greatly influenced by missing data classifying the disability status data for three patients in the conventional management group. These patients were simply lost to follow-up. However, as survival has not been shown to be significantly different between groups, it is hard to imagine why those who survive, post ECMO, do so with less severe disability.

When recruiting subjects, the authors used the LIS described by Murray et al.1 rather than the definitions for acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) produced following a 1994 consensus conference,4 a Murray score >3 being the primary inclusion factor. This is not a concern given previous evidence that these scoring systems can be used interchangeably.1 It is worth noting that such scores have not been shown in clinical trials to be predictive of mortality in severe respiratory failure.5 It is therefore reasonable to assume that a validated, mortality-predictive scoring system, if it existed, could better...
widespread use of this treatment modality.

Lower degree of disability remains outstanding, this adjusted life years. However, as an explanation for the risk of death is not statistically different, it is difficult to justify the routine use of this form of therapy. Those who survive ECMO can be recommended as routine treatment. At present it should remain a salvage therapy.

A potential detrimental effect is noted in the treatment limb related to the pre-ECMO protocol allowing transfusion to a packed cell volume of 40%. Transfusion of critically ill patients to a haemoglobin concentration of approximately 13.3 g/dl would not be standard practice. Following the TRICC study² and more recent meta-analyses on the subject describing the detrimental effects of over-transfusion, the protocol-driven liberal transfusion policy may have influenced the CESAR trial’s survival results.

The cost of treatment with ECMO is estimated at more than twice the cost of conventional treatment. Given that the risk of death is not statistically different, it is difficult to justify the routine use of this form of therapy. Those who survive ECMO seem to do so with less disability and this could have an economic benefit in terms of quality-adjusted life years. However, as an explanation for the lower degree of disability remains outstanding, this economic argument cannot yet be used to justify more widespread use of this treatment modality.

The CESAR trial does provide some positive results. Reported survival rates of 63% in the ECMO limb and 51% in the conventional limb are improved compared with historical mortality figures for acute severe respiratory failure in similar studies. Mortality rates in the 1970s for patients with acute severe respiratory failure were typically in the order of 90%. What has also been successfully demonstrated is the relative safety of the entire ECMO process. Significant levels of iatrogenic harm have not been highlighted, in contrast to the levels of morbidity reported in previous trials.¹²

As more patients survive, critical illness consideration of the need for post-ICU care is pertinent. The authors have meticulously gathered data documenting various health outcomes as secondary outcome measures. The results add evidence to the need for continued care following hospital discharge. The healthcare outcomes point toward clinically significant levels of respiratory dysfunction, disability, anxiety, depression and chronic pain. Many surviving patients will therefore consume significant healthcare resources and require input from a wide range of healthcare professionals to facilitate rehabilitation.

When conducting a randomised control trial of life-saving therapy, in a heterogeneous group, there will be potential shortcomings. This is not a new phenomenon in the setting of ICU trials and in this case the shortcomings are largely insurmountable. Considering the group of patients and the intervention under scrutiny, the trial has been well designed and executed. It has tried to answer two very difficult questions: is ECMO in severe adult respiratory failure both worthwhile and cost-effective? I believe that it has not provided enough evidence to justify the conclusion drawn from the study. However, as a treatment of last resort, particularly during the recent H1N1 epidemic, it has likely been invaluable and has without doubt saved lives. This alone justifies the existence and potentially the expansion of an ECMO service. This study provides good phase 2 data from a single centre, but needs a large multicentre trial to confirm benefit before ECMO can be recommended as routine treatment. At present it should remain a salvage therapy.

REFERENCES


